EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Maribavir for Refractory Cytomegalovirus Infection in Transplant Recipients: A Single-Center Real-World Case Series with Tailored Therapeutic Management

Biagio Pinchera, Alessia D’Agostino, Stefano Mario Susini, Maria Michela Scirocco, Fabrizio Salemi, Amerigo Piccione, Rosa Carrano, Ivan Gentile

Acta Microbiologica Hellenica · 17.08.2026 · 71 (3) · 29

DOI: 10.3390/amh71030029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Microbiologica Hellenica, online erschienen am 17.08.2026. Verfasst von Biagio Pinchera und 7 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Refractory cytomegalovirus (CMV) infection remains a major challenge after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Maribavir has demonstrated efficacy and a favorable safety profile in clinical trials, but real-world data on virological endpoints, treatment duration, and recurrence remain limited.

Methods

We retrospectively reviewed all consecutive transplant recipients treated with maribavir for refractory CMV infection/disease at a tertiary referral center in Naples, Italy. Clinical and laboratory information were extracted from medical records.

Results

Six patients were included: five SOT recipients and one autologous HSCT recipient. Maribavir was administered at 400 mg twice daily for a median of 43.5 days (IQR 23–56 days). At the end of treatment, five patients had detectable CMV DNA < 1000 IU/mL without confirmed clearance. Patient 6 was the only patient to achieve confirmed clearance (

Zitieren

APA

Pinchera, B., D’Agostino, A., Susini, S. M., Scirocco, M. M., Salemi, F., Piccione, A., Carrano, R., & Gentile, I. (2026). Maribavir for Refractory Cytomegalovirus Infection in Transplant Recipients: A Single-Center Real-World Case Series with Tailored Therapeutic Management. Acta Microbiologica Hellenica, 71(3), 29. https://doi.org/10.3390/amh71030029

Vancouver

Pinchera B, D’Agostino A, Susini SM, Scirocco MM, Salemi F, Piccione A, et al. Maribavir for Refractory Cytomegalovirus Infection in Transplant Recipients: A Single-Center Real-World Case Series with Tailored Therapeutic Management. Acta Microbiologica Hellenica. 2026;71(3):29. doi:10.3390/amh71030029

BibTeX
@article{Pinchera2026,
  author = {Pinchera, Biagio and D’Agostino, Alessia and Susini, Stefano Mario and Scirocco, Maria Michela and Salemi, Fabrizio and Piccione, Amerigo and Carrano, Rosa and Gentile, Ivan},
  title = {Maribavir for Refractory Cytomegalovirus Infection in Transplant Recipients: A Single-Center Real-World Case Series with Tailored Therapeutic Management},
  journal = {Acta Microbiologica Hellenica},
  year = {2026},
  volume = {71},
  number = {3},
  pages = {29},
  doi = {10.3390/amh71030029}
}
Kostenlos starten →